S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Joint Stock Forecast, Price & News

-4.51 (-5.93%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
216,662 shs
Average Volume
141,536 shs
Market Capitalization
$1.03 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive JYNT News and Ratings via Email

Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter.

Joint logo

About Joint

The Joint Corp. (United States) engages in the development, ownership, operation, support and management of chiropractic clinics. It operates through two segments: Corporate Clinics and Franchise Operations. The Corporate Clinics segment comprises of the operating activities of the company owned or managed clinics. The Franchise Operations segment includes the operating activities of the franchise business unit. The Joint was founded by Fred Gerretzen, Charles Barnwell, John Leonesio, Todd Welker, Barbara Holland, Steven P. Colmar, Craig P. Colmar and Richard Rees on March 10, 2010 and is headquartered in Scottsdale, AZ.


Joint (NASDAQ:JYNT) Trading Down 7.3%
December 2, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Patent owners & lessors
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$58.68 million
Cash Flow
$0.47 per share
Book Value
$2.02 per share


Net Income
$13.17 million
Pretax Margin




Free Float
Market Cap
$1.03 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.09 out of 5 stars

Medical Sector

533rd out of 1,388 stocks

Patent Owners & Lessors Industry

6th out of 12 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

Joint (NASDAQ:JYNT) Frequently Asked Questions

Is Joint a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Joint in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Joint stock.
View analyst ratings for Joint
or view top-rated stocks.

How has Joint's stock been impacted by Coronavirus (COVID-19)?

Joint's stock was trading at $13.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, JYNT shares have increased by 426.1% and is now trading at $71.60.
View which stocks have been most impacted by COVID-19

When is Joint's next earnings date?

Joint is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Joint

How were Joint's earnings last quarter?

The Joint Corp. (NASDAQ:JYNT) announced its quarterly earnings results on Thursday, November, 4th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.09. Joint had a net margin of 23.18% and a trailing twelve-month return on equity of 34.65%. During the same quarter in the prior year, the business posted $0.11 EPS.
View Joint's earnings history

What guidance has Joint issued on next quarter's earnings?

Joint issued an update on its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $80 million-$81 million, compared to the consensus revenue estimate of $79.42 million.

What price target have analysts set for JYNT?

6 equities research analysts have issued 12-month price targets for Joint's stock. Their forecasts range from $54.00 to $150.00. On average, they anticipate Joint's stock price to reach $107.83 in the next year. This suggests a possible upside of 50.6% from the stock's current price.
View analysts' price targets for Joint
or view top-rated stocks among Wall Street analysts.

Who are Joint's key executives?

Joint's management team includes the following people:
  • Peter D. Holt, President, Chief Executive Officer & Director
  • Jorge Armenteros, Vice President-Operations
  • Jacob Singleton, Chief Financial Officer & Controller (LinkedIn Profile)
  • Manjula Sriram, Vice President-Information Technology
  • Steve Knauf, Executive Director-Chiropractic & Compliance

What is Peter D. Holt's approval rating as Joint's CEO?

87 employees have rated Joint CEO Peter D. Holt on Glassdoor.com. Peter D. Holt has an approval rating of 59% among Joint's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Joint own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Joint investors own include Aurora Cannabis (ACB), Advanced Micro Devices (AMD), Raytheon Technologies (RTX), salesforce.com (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE).

When did Joint IPO?

(JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager.

What is Joint's stock symbol?

Joint trades on the NASDAQ under the ticker symbol "JYNT."

Who are Joint's major shareholders?

Joint's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.81%), Next Century Growth Investors LLC (2.43%), Skylands Capital LLC (2.30%), Dimensional Fund Advisors LP (2.03%), Invesco Ltd. (1.78%) and Geode Capital Management LLC (1.61%). Company insiders that own Joint stock include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Matthew E Rubel, Matthew E Rubel and Ronald V Davella.
View institutional ownership trends for Joint

Which major investors are selling Joint stock?

JYNT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Next Century Growth Investors LLC, Victory Capital Management Inc., Skylands Capital LLC, Wolverine Trading LLC, Invesco Ltd., Wasatch Advisors Inc., and Adell Harriman & Carpenter Inc.. Company insiders that have sold Joint company stock in the last year include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Matthew E Rubel, and Ronald V Davella.
View insider buying and selling activity for Joint
or view top insider-selling stocks.

Which major investors are buying Joint stock?

JYNT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Caption Management LLC, HAP Trading LLC, Dimensional Fund Advisors LP, Citadel Advisors LLC, Jane Street Group LLC, Renaissance Technologies LLC, and Morgan Stanley. Company insiders that have bought Joint stock in the last two years include Bandera Partners Llc, and Jake Singleton.
View insider buying and selling activity for Joint
or or view top insider-buying stocks.

How do I buy shares of Joint?

Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Joint's stock price today?

One share of JYNT stock can currently be purchased for approximately $71.60.

How much money does Joint make?

Joint has a market capitalization of $1.03 billion and generates $58.68 million in revenue each year. The company earns $13.17 million in net income (profit) each year or $1.19 on an earnings per share basis.

How many employees does Joint have?

Joint employs 325 workers across the globe.

What is Joint's official website?

The official website for Joint is www.thejoint.com.

Where are Joint's headquarters?

How can I contact Joint?

Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at (480) 245-5960, via email at [email protected], or via fax at 480-513-7989.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.